Integra LifeSciences Faces Investor Probe After Revenue Guidance Cut

The stock decline was triggered by preliminary third-quarter revenue figures of $410 million to $412 million, falling short of the $416.3 million consensus estimate. Beyond the immediate shortfall, Integra lowered its full-year revenue guidance to a range of $1.634 billion to $1.654 billion. The company attributed this downturn to the Cincinnati facility damage, which impacted third-quarter results by approximately $7 million and is expected to further reduce fourth-quarter revenue by up to $20 million.

Legal firm Levi & Korsinsky, operating under the SueWallSt banner, has launched an investigation into potential securities claims. The inquiry centers on whether previous statements made by management regarding the financial impact of the flooding were misleading. During an earnings call on July 29, 2026, Chief Financial Officer Lea Daniels Knight told investors the company did not expect the event to materially affect its 2026 guidance. Shareholders who incurred losses following the subsequent stock price drop are now being evaluated for potential recovery actions.